[go: up one dir, main page]

MX2014004473A - Imidazo [1,2-c] pirimidinas 5,7-substituidas. - Google Patents

Imidazo [1,2-c] pirimidinas 5,7-substituidas.

Info

Publication number
MX2014004473A
MX2014004473A MX2014004473A MX2014004473A MX2014004473A MX 2014004473 A MX2014004473 A MX 2014004473A MX 2014004473 A MX2014004473 A MX 2014004473A MX 2014004473 A MX2014004473 A MX 2014004473A MX 2014004473 A MX2014004473 A MX 2014004473A
Authority
MX
Mexico
Prior art keywords
pyrimidines
imidazo
substituted
morbidities
malignancies
Prior art date
Application number
MX2014004473A
Other languages
English (en)
Inventor
John E Robinson
Bruno P Hache
David A Moreno
Mark Laurence Boys
Laurence E Burgess
C Todd Eary
Robert Groneberg
Darren Harvey
Erik James Hicken
Christopher F Kraser
Ellen Laird
Mark C Munson
Li Ren
Stephen T Schlachter
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of MX2014004473A publication Critical patent/MX2014004473A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen compuestos de Fórmula I; y estereoisómeros y sales farmacéuticamente aceptables de estos, donde R1, R2, R3, R4, R5, R6, X1 y X2 tienen los significados que se proporcionan en la memoria descriptiva, son inhibidores de una o más cinasas JAK y son útiles en el tratamiento de enfermedades autoinmunitarias, enfermedades inflamatorias, rechazo de órganos, tejidos y células transplantadas, así como neoplasias y trastornos hematológicos y sus comorbilidades.
MX2014004473A 2011-10-12 2012-10-09 Imidazo [1,2-c] pirimidinas 5,7-substituidas. MX2014004473A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161546426P 2011-10-12 2011-10-12
PCT/US2012/059282 WO2013055645A1 (en) 2011-10-12 2012-10-09 5,7-substituted-imidazo[1,2-c]pyrimidines

Publications (1)

Publication Number Publication Date
MX2014004473A true MX2014004473A (es) 2015-04-14

Family

ID=47071473

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014004473A MX2014004473A (es) 2011-10-12 2012-10-09 Imidazo [1,2-c] pirimidinas 5,7-substituidas.

Country Status (20)

Country Link
US (1) US20140228349A1 (es)
EP (1) EP2766368A1 (es)
JP (1) JP2014528475A (es)
KR (1) KR20140076619A (es)
CN (1) CN103987713A (es)
AR (1) AR088304A1 (es)
AU (1) AU2012323399A1 (es)
BR (1) BR112014008865A2 (es)
CA (1) CA2851623A1 (es)
CL (1) CL2014000931A1 (es)
CO (1) CO6950483A2 (es)
CR (1) CR20140216A (es)
IL (1) IL231903A0 (es)
MX (1) MX2014004473A (es)
PH (1) PH12014500730A1 (es)
RU (1) RU2014118954A (es)
SG (1) SG11201401342VA (es)
TW (1) TW201326173A (es)
UY (1) UY34388A (es)
WO (1) WO2013055645A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2634185T3 (pl) 2012-03-02 2016-06-30 Sareum Ltd Inhibitory kinazy TYK2
JP6485817B2 (ja) 2013-08-21 2019-03-20 ヤンセン バイオファーマ インク． 抗ウイルス化合物
MX369974B (es) * 2013-09-03 2019-11-27 Sareum Ltd Compuestos farmaceuticos.
DK3227297T3 (da) * 2014-12-05 2021-04-06 Array Biopharma Inc 4,6-substitueret-pyrazolo[1,5-a]pyraziner som janus kinase-inhibitorer
CN108349977B (zh) 2015-01-20 2021-05-25 无锡福祈制药有限公司 Jak抑制剂
EP3290418B1 (en) 2015-04-29 2019-05-15 Wuxi Fortune Pharmaceutical Co., Ltd Janus kinase (jak) inhibitors
UA118822C2 (uk) 2015-05-29 2019-03-11 Вуксі Фортуне Фармасьютікал Ко., Лтд Інгібітор янус-кінази
UA119835C2 (uk) 2016-02-24 2019-08-12 Пфайзер Інк. ПОХІДНІ ПІРАЗОЛО[1,5-а]ПІРАЗИН-4-ІЛУ ЯК JAK-ІНГІБІТОРИ
GB201617871D0 (en) 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
US11254668B2 (en) 2017-08-14 2022-02-22 Pfizer Inc. Pyrazolo[1,5-A]pyrazin-4-yl and related derivatives
JP7083203B2 (ja) * 2018-06-06 2022-06-10 ジェングル セラピューティクス，インコーポレイテッド ピラゾロピリミジン誘導体、その用途並びに医薬組成物
US20220041588A1 (en) * 2018-09-27 2022-02-10 Fochon Pharmaceuticals, Ltd. Substituted imidazo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine compounds as ret kinase inhibitors
GB201816369D0 (en) 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds
KR102658602B1 (ko) 2018-10-31 2024-04-19 길리애드 사이언시즈, 인코포레이티드 Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
EP4371987B9 (en) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
CN111320624B (zh) * 2018-12-14 2023-05-12 中国医药研究开发中心有限公司 三唑并吡啶类和咪唑并吡啶类化合物及其制备方法和医药用途
MX2021012487A (es) 2019-04-12 2021-11-12 Primegene Beijing Co Ltd Compuestos derivados de pirazolopirazina, composicion farmaceutica y uso de la misma.
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
CN111039963B (zh) * 2019-12-31 2021-03-19 卓和药业集团有限公司 Wxfl10203614水溶性类似物及其合成方法
WO2021173476A1 (en) 2020-02-24 2021-09-02 The Trustees Of Columbia University In The City Of New York Compounds, pharmaceutical formulations, and methods for treatment of cancer
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
JP2023549360A (ja) * 2020-11-13 2023-11-24 バイオジェン・エムエイ・インコーポレイテッド Ｂｔｋ阻害剤としてのピラゾロ［１，５－ａ］ピラジン誘導体
IL304886B2 (en) 2021-03-04 2025-08-01 Lilly Co Eli Fgfr3 inhibitor compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010089171A (ko) 1998-08-21 2001-09-29 추후제출 퀴나졸린 유도체
JP2001302667A (ja) * 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
EP2343298B9 (en) * 2005-12-13 2020-05-06 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
CN103288833B (zh) * 2006-11-22 2018-01-12 因塞特控股公司 作为激酶抑制剂的咪唑并三嗪和咪唑并嘧啶
DE102007012645A1 (de) * 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
CL2008001709A1 (es) * 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
CN102985424B (zh) * 2010-04-14 2015-03-11 阵列生物制药公司 5,7-取代的-咪唑并[1,2-c]嘧啶

Also Published As

Publication number Publication date
AR088304A1 (es) 2014-05-21
RU2014118954A (ru) 2015-11-20
EP2766368A1 (en) 2014-08-20
US20140228349A1 (en) 2014-08-14
JP2014528475A (ja) 2014-10-27
CO6950483A2 (es) 2014-05-20
CL2014000931A1 (es) 2014-08-29
CN103987713A (zh) 2014-08-13
SG11201401342VA (en) 2014-09-26
CR20140216A (es) 2014-08-21
AU2012323399A1 (en) 2014-05-29
CA2851623A1 (en) 2013-04-18
IL231903A0 (en) 2014-05-28
TW201326173A (zh) 2013-07-01
UY34388A (es) 2014-04-30
KR20140076619A (ko) 2014-06-20
PH12014500730A1 (en) 2018-01-17
BR112014008865A2 (pt) 2017-04-25
WO2013055645A1 (en) 2013-04-18

Similar Documents

Publication Publication Date Title
PH12014500730A1 (en) 5,7-substituted-imidazo[1,2-c]pyrimidines
PH12012502046A1 (en) 5,7-substituted~imidazo[1,2-c]pyrimidines as inhibitors of jak kinases
PH12017501032A1 (en) 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS
MY156727A (en) N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
MX376465B (es) Compuestos de pirazolo[1,5-4]piridina sustituidos como inhibidores de la quinasa ret.
PH12016502168B1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
UA116774C2 (uk) Інгібітори серин/треонінкінази
EA201390736A1 (ru) Циклобутилзамещенные производные пирролопиридина и пирролопиримидина как ингибиторы jak
UA112425C2 (uk) ЗАМІЩЕНІ N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗО[1,2-a]ПІРИДИН-3-КАРБОКСАМІДНІ СПОЛУКИ ЯК ІНГІБІТОРИ РЕЦЕПТОРНОЇ ТИРОЗИНКІНАЗИ ІІІ ТИПУ
UA111756C2 (uk) Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
MX2014005285A (es) Compuestos biciclicos de piperazina.
MX2014005282A (es) Compuestos de 8-fluoroftalazin-1 (2h) -ona.
MX2014001239A (es) Compuestos de pirazolo [3,4-c] piridina y metodos de uso.
UA115320C2 (uk) Інгібітори кінази
MX2012006822A (es) 1,7-diazacarbazoles y metodos de uso.
IN2015DN03751A (es)
MX2012002327A (es) Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.
TN2012000370A1 (en) 5-alkynyl pyrimidines and their use as kinase inhibitors

Legal Events

Date Code Title Description
FA Abandonment or withdrawal